drugset
drugset / Trial / NCT01232127

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

NCT01232127 ↗

Phase 4 Completed 25 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.

Timeline

Start
2011-02
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg Oral
Subject Atazanavir Other / unclassified 400 mg Oral
Subject Famotidine Other / unclassified 20 mg Oral
Subject Famotidine Other / unclassified 40 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral
Background Tenofovir Small molecule 300 mg Oral

Indications

HIV infectious disease